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BACKGROUND: Alirocumab, a monoclonal antibody to proprotein convertase 
subtilisin/kexin type 9 (PCSK9), lowers plasma low-density lipoprotein (LDL) 
cholesterol and apolipoprotein B100 (apoB). Although studies in mice and cells 
have identified increased hepatic LDL receptors as the basis for LDL lowering 
by PCSK9 inhibitors, there have been no human studies characterizing the 
effects of PCSK9 inhibitors on lipoprotein metabolism. In particular, it is 
not known whether inhibition of PCSK9 has any effects on very low-density 
lipoprotein or intermediate-density lipoprotein (IDL) metabolism. Inhibition of 
PCSK9 also results in reductions of plasma lipoprotein (a) levels. The regulation 
of plasma Lp(a) levels, including the role of LDL receptors in the clearance of 
Lp(a), is poorly defined, and no mechanistic studies of the Lp(a) lowering by 
alirocumab in humans have been published to date.
METHODS: Eighteen (10 F, 8 mol/L) participants completed a placebo-
controlled, 2-period study. They received 2 doses of placebo, 2 weeks 
apart, followed by 5 doses of 150 mg of alirocumab, 2 weeks apart. At the 
end of each period, fractional clearance rates (FCRs) and production rates 
(PRs) of apoB and apo(a) were determined. In 10 participants, postprandial 
triglycerides and apoB48 levels were measured.
RESULTS: Alirocumab reduced ultracentrifugally isolated LDL-C by 55.1%, 
LDL-apoB by 56.3%, and plasma Lp(a) by 18.7%. The fall in LDL-apoB was 
caused by an 80.4% increase in LDL-apoB FCR and a 23.9% reduction in LDL-
apoB PR. The latter was due to a 46.1% increase in IDL-apoB FCR coupled with 
a 27.2% decrease in conversion of IDL to LDL. The FCR of apo(a) tended to 
increase (24.6%) without any change in apo(a) PR. Alirocumab had no effects 
on FCRs or PRs of very low-density lipoproteins-apoB and very low-density 
lipoproteins triglycerides  or on postprandial plasma triglycerides or apoB48 
concentrations.
CONCLUSIONS: Alirocumab decreased LDL-C and LDL-apoB by increasing 
IDL- and LDL-apoB FCRs and decreasing LDL-apoB PR. These results are 
consistent with increases in LDL receptors available to clear IDL and LDL from 
blood during PCSK9 inhibition. The increase in apo(a) FCR during alirocumab 
treatment suggests that increased LDL receptors may also play a role in the 
reduction of plasma Lp(a).
CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique 
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Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted member of the subtilase fam-ily of serine proteases. PCSK9 binds to hepatic low-
density lipoprotein receptors (LDLRs) and targets them, 
together with bound LDLs for degradation rather than re-
cycling. As a result, PCSK9 reduces the number of func-
tional LDLRs on cell surfaces, thereby increasing levels 
of LDL-cholesterol (LDL-C) in the blood.1,2 Alirocumab is 
a fully human monoclonal antibody that specifically binds 
to PCSK9 and inhibits PCSK9 binding to, and PCSK9-
mediated degradation of, LDLRs. As a result, alirocumab 
treatment substantially decreases blood levels of LDL-C 
and apolipoprotein B (apoB).3–5
Based on the mechanism of PCSK9 action, it has been 
postulated that alirocumab lowers blood levels of LDL-
C and apoB by increasing LDLRs in the liver, leading to 
increased efficiency of the removal of LDL particles from 
the circulation. However, apoB enters the circulation from 
the liver on very low-density lipoproteins (VLDLs), which 
are converted first to intermediate-density lipoproteins 
(IDLs) and, subsequently, to LDL. During this process, 
both VLDL and IDL particles may leave the bloodstream 
by interacting with LDLRs, particularly in the liver.6–8 Thus, 
drugs that reduce blood levels of LDL-C can mediate their 
effects through pathways other than the classical LDLR-
mediated uptake of LDL, such as by reducing the initial 
secretion of VLDL or the conversion of VLDL and IDL to 
LDL. The purpose of this study was to evaluate the ef-
fects of alirocumab on the flux of apoB from its entry into 
the circulation as VLDL, through IDL and LDL. In addition, 
we determined the effects of PCSK9 inhibition on the me-
tabolism of VLDL triglyceride (TG) and levels of TG-rich 
lipoproteins during the postprandial (PP) period.
An unexpected finding in early clinical trials was a re-
duction in lipoprotein (a) levels with inhibition of PCSK9 
activity.9,10 The role of the LDLR in the removal of Lp(a) 
from the circulation remains controversial. For example, 
statins, which increase LDLRs significantly, do not re-
duce or may even increase plasma Lp(a) levels.11 We 
also, therefore, conducted an exploratory study of the 
effects of inhibition of PCSK9 on the metabolism of Lp(a).
METHODS
Study Subjects
We enrolled 20 healthy volunteers, 18 to 65 years of age, with 
LDL-C levels >90 mg/dL. Subjects were recruited from internal 
clinical trial databases, advertisements, and postings at the 
Columbia University Medical Center (CUMC). Participants were 
not receiving lipid-lowering medications. All subjects of child-
bearing capacity agreed to use birth control for the duration 
of the study and had a negative serum pregnancy test when 
applicable. This study was conducted in accordance with the 
principles of Good Clinical Practice and was approved by the 
CUMC Institutional Review Board. All study subjects provided 
written informed consent.
Study Design
This was a Phase 1, placebo-controlled, single-blind, single-
sequence, 2-period study (http://www.clinicaltrials.gov. Unique 
identifier: NCT01959971; for the study design, see online-only 
Data Supplement Figure I). All subjects were instructed on 
adherence to the American Heart Association Heart Healthy 
Diet guidelines during the study and were regularly checked 
for dietary compliance. Participants received 2 subcutaneous 
injections of placebo every 2 weeks  followed immediately by 5 
subcutaneous injections of alirocumab, 150 mg every 2 weeks. 
Studies of PP lipemia were conducted 2 weeks after the first 
placebo injection and again immediately after 5 doses of ali-
rocumab. Lipoprotein kinetic studies were performed 2 weeks 
after completion of placebo treatment and 2 weeks after the 
last alirocumab dose. For each participant, a comparison of 
study outcomes across the 2 treatment periods (placebo vs 
alirocumab) was performed. Thus, each person served as his 
or her own control.
Safety
Alirocumab is a US Food and Drug Administration–approved 
lipid-altering treatment. The safety of alirocumab and its 
Clinical Perspective
What Is New?
• In this study of healthy volunteers, we demonstrated 
that the marked reductions in low-density lipopro-
tein  (LDL) cholesterol levels observed when propro-
tein convertase subtilisin/kexin type 9 (PCSK9) is 
inhibited by the monoclonal antibody, alirocumab, 
are caused by a dramatic increase in the efficiency 
of removal of atherogenic LDL particles from the 
circulation.
• We also observed reduced production of LDL-apo-
lipoprotein B resulting from increased efficiency of 
removal of intermediate density lipoproteins and, 
therefore, less production of LDL.
• These findings are the first human data support-
ing earlier studies in cells and mice that showed 
increased LDL receptor (LDLR) activity when PCSK9 
is inhibited.
What Are the Clinical Implications?
• The role of the LDLR in regulating blood levels of 
atherogenic apolipoprotein B lipoproteins, particu-
larly LDL, is clear, as are the benefits of increasing 
the capacity of the LDLR pathway for cardiovascular 
disease risk.
• The discovery that PCSK9 reduces LDLRs on the 
surface of cells by targeting the receptor for degra-
dation stimulated development of PCSK9 inhibitors.
• Our study, which demonstrates that inhibition of 
PCSK9 with alirocumab increases the removal of 
LDL from the circulation by the LDLR, increases con-
fidence that PCSK9 inhibitors will confer clinical ben-
efit in the ongoing cardiovascular outcome trials.
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effects on blood lipids have been previously reported for men 
and women.5,10 Safety data were closely monitored with clinical 
and laboratory assessments throughout the study (see online-
only Data Supplement for further details).
Biochemical Assays
Blood was collected at the end of each treatment period after 
a 12-hour fast. Plasma total cholesterol, TG, high-density lipo-
protein cholesterol (HDL-C), apoC-III, and apoE were measured 
by Human Elisa Kits (ab154131 [apoC3]; ab108813 [apoE], 
Abcam, Cambridge, MA). Plasma LDL-C levels were estimated 
using the Friedewald formula. Cholesterol and TG were also 
measured enzymatically in VLDL, IDL, LDL, and HDL isolated 
by ultracentrifugation.12 ApoB in plasma and in VLDL, IDL, and 
LDL was measured using an apoB enzyme-linked immunosor-
bent assay (ELISA) kit (AlerCheck, Inc.). Plasma Lp(a) levels 
were measured using a monoclonal antibody-based ELISA 
method validated to accurately measure Lp(a) independently 
of the number of repeats in Kringle IV type 2.13 Apo(a) iso-
forms were assayed with methodology previously described,14 
in which the isoform size visualized on agarose gel electropho-
resis is directly proportional to the number of Kringle IV type 2 
repeats. In some subjects, only 1 apo(a) isoform is expressed. 
In most individuals, however, apo(a) is expressed by both 
alleles, with 1 isoform more prevalent than the other. Particle 
sizes and number were determined by ion mobility analysis.15 
Lathosterol, campesterol, and β-sitosterol were measured by 
gas chromatography as previously described.16
Serum levels of anti-alirocumab antibodies (ADA) and free 
PCSK9 were assayed by Regeneron Pharmaceuticals, Inc., 
Tarrytown, NY (see online-only Data Supplement). Serum 
samples were assayed for ADAs using a validated immuno-
assay developed by Regeneron Pharmaceuticals, Inc. In brief, 
this titer-based, bridging immunoassay used a Meso Scale 
Discovery electrochemiluminescence instrument (Rockville, 
MD). The assay comprised 3 different stages: an initial screen-
ing assay to identify potentially ADA-positive samples, a confir-
mation assay based on competition with exogenously added 
alirocumab, and a determination of the titer of ADA for con-
firmed positive samples.
Free PCSK9 levels in serum were determined using specific 
validated enzyme-linked immunosorbent assays developed by 
Regeneron Pharmaceuticals, Inc. The lower limit of detection 
of free PCSK9 was 31.2 ng/mL.
Hepatic Lipase (HL) and Lipoprotein Lipase 
(LpL) Activity Measurements
Post-heparin plasma was collected 15 minutes after an i.v. 
injection of heparin (60 U/kg body weight [BW]) on 2 occa-
sions: after subjects had received 2 doses of placebo and 
after they had received 5 doses of alirocumab (see online-only 
Data Supplement).
Stable Isotope Kinetic Studies
Participants were admitted to the inpatient unit of the Irving 
Institute for Clinical and Translational Research (IICTR) at CUMC 
for 2.5 days. On day 1, fasting bloods were obtained, and 
meals for the day were provided. At 1 am on the morning of 
day 2, constant feedings of an isocaloric, 18% fat diet began 
and continued every 2 hours for 32 hours. At 9 am, boluses 
of 2H3-L-leucine (10 μmol/kg BW), Ring-
13C6-L-phenylalanine 
(29.4 μmol/kg BW), and 2H5-glycerol (100 μmol/kg BW) were 
administered over a 10-minute period, followed by a constant 
infusion of 2H3-L-leucine (10 μmol/kg BW/hr) over 15 hours. 
Blood samples were collected at 0 (prebolus), 20, and 40 
minutes and at 1, 2, 4, 6, 8, 10, 12, 14, 15, 15.5, 16, 18, 
21, 24, and 48 hours and processed to isolate VLDL, IDL, 
LDL, and HDL.12,17
Determination of Stable Isotopic Enrichment 
of apoB and TG
The lipoprotein fractions isolated during each turnover study 
were used to determine stable isotopic enrichments of apoB 
in VLDL, IDL, and LDL with 2H3-L-leucine (10 μmol/kg BW) and 
Ring-13C6-L-phenylalanine (29.4 μmol/kg BW). Additionally, 
kinetic analysis of TG in VLDL was performed with2H5-glycerol 
(100 μmol/kg BW). ApoB was isolated from VLDL, IDL, and 
LDL by SDS gel electrophoresis. Enrichment of leucine and 
phenyalanine in apoB lipoproteins and plasma-free leucine and 
phenylalanine enrichment was measured by gas chromatogra-
phy–mass spectrometry using an Agilent 6890 gas chromato-
graph and a 5973 mass spectrometer using negative chemical 
ionization.12 The enrichment of TG-glycerol was determined by 
gas chromatography–mass spectrometry using positive chemi-
cal ionization after derivatization of glycerol to triacetin.12
Mathematical Modeling of the apoB 
and TG Enrichment Data
A multicompartmental model was used to estimate apoB and 
TG rate constants and fluxes from the enrichment data.18 ApoB 
and TG were required to have the same pool structure for VLDL 
and the same rate constants for the VLDL pools but with differ-
ent mass distributions. The minimum number of pools needed 
to fit the 9 sets of data (2 tracers, leucine and phenylalanine, 
in VLDL-, IDL-, and LDL-apoB and plasma amino acids, and 1 
tracer, glycerol, in VLDL-TG simultaneously was chosen for 
the final model).17 The data were fitted by least squares using 
a computer program, Poolfit,19 which solves the differential 
equations in closed form and computes the fits and parameter 
sensitivities as sums of exponentials. The fits yielded FCRs of 
apoB in VLDL, IDL, and LDL and of TG in VLDL. The model 
also estimated rates of conversion of apoB between VLDL and 
IDL, and IDL and LDL. PRs were calculated by multiplying FCRs 
by the appropriate lipoprotein pool sizes of apoB, which were 
estimated as each lipoprotein’s concentration of apoB in mg/dL 
multiplied by plasma volume (taken as 45 mL/kg BW).
Determination of Stable Isotope 
Enrichment of apo(a)
Apo(a) enrichment with 2H3-L-leucine was measured as 
described by Zhou et al .20 In brief, equal volumes (100 µL) of 
ultracentrifuged fractions of LDL and HDL, which together hold 
95% of plasma Lp(a), were combined, desalted, reduced with 
DTT, alkylated with iodoacetamide, and digested using trypsin. 
A multiple reaction monitoring method was used to monitor the 
following precursor product ion transitions to a peptide spe-
cific to apo(a) (LFLEPTQADIALLK): 786.7>1069.7 (M0) and 
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788.2>1069.7 (M3); 2 µL of the digested samples were ana-
lyzed using a nanoAcquity ultraperformance liquid chromatogra-
phy system coupled with an ionKey source integrated to a Xevo 
TQS triple quad tandem mass spectrometer (Waters, Milford, 
MA). The separation was achieved using an iKey Peptide BEH 
C18 separation device (130 Å, 1.7 µm, 150 µm X 100 mm) 
maintained at 60°C. The gradient was 90% A (0.1% formic acid 
in water)/10% B (0.1% formic acid in acetonitrile) ramped lin-
early to 10% A at 6 minutes, held for 3 minutes, and then re-
equilibrated to initial conditions (total run time: 12 minutes; flow 
rate: 3 µL/min). The multiple reaction monitoring transitions 
were monitored with a collision energy of 24 eV.
Apo(a) Modeling
The apo(a) enrichment data were modeled as previously 
described for apoC-III.17 Briefly, we estimated apo(a) FCR by 
fitting the leucine enrichment in the apo(a) protein with a single-
pool model, with the precursor enrichment set at the same 
level as found with the apoB model described earlier. Apo(a) PR 
in nM/kg/d was calculated as the product of apo(a) FCR and 
the molar pool size per kg BW of apo(a), which is the apo(a) 
concentration (nM) multiplied by the plasma volume (taken as 
45 mL/kg BW).
Post-Prandial Lipemia Studies
PP TG and apoB48 levels were measured after consumption 
of a standard high-fat liquid meal.21 Details of the protocol are 
found in the online-only Data Supplement.
Statistical Analysis
The corresponding authors had full access to all the data and 
take responsibility for its integrity and the data analysis. The pri-
mary end point was the change in LDL-apoB FCR from the end of 
placebo treatment to the end of alirocumab treatment. With 18 
subjects completing the protocol, the study had 80% power to 
see a 35% change in LDL-apoB FCR, assuming an FCR of 0.42 
pools/day at the end of the placebo treatment period using a 
2-sided paired t test with an alpha of 0.05. Prespecified second-
ary analyses included FCRs of VLDL- and IDL-apoB, PRs of VLDL-, 
IDL-, and LDL-apoB, conversion of VLDL to LDL and IDL to LDL, 
FCR and PR of VLDL-TG, plasma concentrations of Lp(a), FCR 
and PR of apo(a), lipoprotein size and number, and postheparin 
plasma LpL and HL activities at the end of placebo and alirocumab 
treatment periods. Exploratory analyses included levels of plant 
sterols, apoCIII, and apoE at the end of each treatment period. All 
secondary and exploratory analyses are presented with nominal 
P-values uncorrected for multiple comparisons. Exploratory out-
comes analyses were performed at CUMC and were not included 
in the original Sanofi study statistical analysis plan.
RESULTS
Eight males (mean age 39.9±9.9 years) and 10 females 
(mean age 47.0±12.2 years) completed the study. Two 
subjects decided to leave the study for personal reasons. 
One dropped out during the placebo period and 1 at the 
end of the placebo period; neither received alirocumab 
(online-only Data Supplement Figure II). No serious ad-
verse events occurred during the study (see online-only 
Data Supplement). Baseline characteristics are shown 
Table 1. Participants had normal plasma glucose levels 
and normal hepatic and renal function. Five doses of ali-
rocumab treatment resulted in significant reductions of 
fasting plasma levels of total cholesterol (34.4%), calcu-
lated LDL-C (57.9%), and apoB (46.6%), with no signifi-
cant effects on plasma HDL-C and TG levels (Table 2).
Alirocumab reduced mean apoB levels in ultracentrifu-
gally isolated IDL (29.9% P≤0.0001) and LDL (56.3% 
P≤0.0001); no significant effect was found on the con-
centration of VLDL-apoB (Table 2). In addition, alirocumab 
treatment resulted in decreased mean levels of choles-
terol and TG concentrations in IDL (41.1%, P≤0.0001 
and 20.9%, P=0.0005, respectively) and LDL (55.1%, 
P≤0.0001 and 35.5%, P≤0.0001, respectively) without 
affecting lipid levels in VLDL (Table 2). The reductions in 
IDL- and LDL-apoB levels measured by ELISA were in ac-
cord with similar reductions in IDL and LDL particle num-
bers determined by ion mobility (online-only Data Supple-
ment Table I). The reduction in LDL particle number was 
associated with a shift toward smaller particles after ali-
rocumab treatment (online-only Data Supplement Table II).
Reductions in IDL- and LDL-apoB concentrations were 
caused by increases in the mean FCRs of these lipopro-
teins (46.1%, P<0.001 and 80.4%, P≤0.0001, respec-
tively) (Figure 1). No significant change occurred in the 
mean VLDL-apoB FCR during alirocumab administration. 
In addition to the marked increase in LDL-apoB FCR, 
mean LDL-apoB PR was reduced by 23.9% (P<0.0001). 
The decrease in the PR of LDL-apoB was caused by the 
significant increase in the FCR of IDL-apoB noted ear-
lier coupled with a mean 27.2% decrease in the conver-
sion of IDL-apoB to LDL-apoB (P<0.005). No significant 
changes were found in the mean VLDL- or IDL-apoB PRs. 
Table 1. Baseline Characteristics: 8 Healthy Men 
and 10 Healthy Women Completed the Study
Parameter Value
Sex, n (%)
  Male 8 (44.4)
  Female 10 (55.6)
Age, y (mean±SD)
  Male 39.9±9.9
  Female 47±12.3
Race, n (%)
  White 3 (17)
  Black 13 (72)
Unknown/mixed race/other 2 (11)
BMI, kg/m2, mean (±SD) 28.1±4.2
BMI indicates body mass index.
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Consistent with alirocumab lack of effects on VLDL-TG 
levels or VLDL-apoB metabolism, no changes occurred 
in mean FCR or PR of VLDL-TG (Figure 2).
Significant correlations were found between base-
line PCSK9 levels and changes in levels of both LDL-C 
(R2 =0.42; P=0.003) and LDL-apoB (R2=0.22; P=0.05) 
(Figure 3).
Apo CIII levels were not different between the 2 study 
periods (8.8±2.4 vs 8.2±1.9 mg/dL), but a 26.9±10.9% 
decrease (P=0.0034) in plasma apo E levels (12.0±3.7 
vs 8.6±2.4 mg/dL) did occur at the end of alirocum-
ab administration (Table 2). Plasma levels of sitosterol 
tended to increase (113.0±37.9 vs 128.4±31.4 µmol 
X 102/mmol cholesterol; P=0.07), whereas levels of 
lathosterol (81.0±33.5 vs 90.4±39.6 µmol X 102/
mmol cholesterol) and campesterol (167.3±54.9 vs 
182.8±53.9 µmol X 102/mmol cholesterol) were unaf-
fected by alirocumab treatments.
Inhibition of PCSK9 caused a reduction in the medi-
an level of plasma Lp(a) of 18.7% compared with pla-
cebo (P<0.01). These reductions were associated with 
a trend for an increase in the median FCR for apo(a) 
(24.6%; P=0.09) with no change in the median apo(a) 
PR (‒9.0%; P=0.6) (Table 3). No significant correlations 
were found between baseline Lp(a) levels and changes 
in Lp(a) levels or apo(a) FCR after alirocumab treatment. 
However, a positive correlation did occur between Lp(a) 
isoform size and changes in apo(a) FCR on alirocumab 
(R2=0.25; P=0.04) (data not shown).
The last 10 subjects enrolled participated in a sub-
study of the effects of alirocumab on PP lipemia. Inhi-
bition of PCSK9 activity by alirocumab had no effects 
on the mean incremental area under the curve above 
baseline of either TG or apoB48 (a marker of chylomi-
crons) during the 8 hours after consumption of a high-fat 
meal (Figure 4). In accord with the absence of effects of 
PCSK9 inhibition on either fasting or PP TG metabolism, 
treatment with alirocumab did not alter the mean levels 
of postheparin HL (0.96±0.6 vs 1.05±0.62 µmol ffa/mL 
plasma/hr) or LpL activities (1.26±0.93 vs1.35±0.90 
µmol ffa/mL plasma/hr) compared with placebo.
DISCUSSION
In this study of the effects of alirocumab, a fully human 
monoclonal antibody against PCSK9, we demonstrated 
that 55% reductions in LDL-C and LDL-apoB were caused 
by a dramatic increase in the efficiency of clearance 
of LDL particles, as evidenced by an 80% increase in 
the FCR of LDL-apoB. We also found a 24% reduction 
in LDL-apoB PR caused by increased efficiency of re-
moval of IDL particles and, therefore, less conversion 
of IDL to LDL. Both of these results are fully consistent 
with marked increases in LDLR mediated by inhibition of 
PCSK9.
The efficacy of alirocumab and other antibodies di-
rected against PCSK922 is compatible with the ability of 
the protein to target the complex of the LDL/LDLR to 
the lysosome for degradation, thereby reducing the re-
cycling of the LDLR that normally occurs after delivery 
of LDL to that organelle.1,2 Earlier studies in cells and ani-
mals supported a model in which inhibition of PCSK9 ac-
tivity leads to increased LDLRs on the surface of the liver 
and increased efficiency of LDL particles removal from 
the circulation (Figure 5). Our results provide evidence in 
humans confirming those preclinical investigations.
The importance of the present results derives from 
the possibility that mechanisms other than more efficient 
LDLR-mediated removal of LDL could account for some 
of the significant reductions in plasma LDL-C and LDL-
apoB levels observed during alirocumab treatment. This 
study explored several potential alternative effects of 
Table 2. Effects of 10 Weeks of Alirocumab 
Treatment* on Plasma Lipids and Lipoproteins
Placebo Alirocumab Change (%) P Value
Plasma Levels: mg/dL (SD)
  Total 
cholesterol
193.1 (32.7) 126.1 (24.6) ‒34 (9.1) <0.0001
 HDL-C 58.6 (15.7) 62.7 (14.1) 8.8 (12.3) NS
 Triglycerides 72.1 (41.4) 63.7 (35.8) ‒8.2 (24.0) NS
 LDL-C† 120.1 (25.0) 50.8 (19.1) ‒57.9 (12.2) <0.0001
 ApoB 100.9 (20.2) 53.6 (13.5) ‒46.6 (10.6) <0.0001
 ApoCIII‡ 8.8 (2.4) 8.2 (1.9) ‒4.2 (24.1) NS
 ApoE‡ 12.0 (3.7) 8.6 (2.4) ‒26.9 (10.9) <0.0001
Lipoprotein apoB and lipid levels¶: mg/dL (SD)
 VLDL-apoB 8.0 (5.9) 6.0 (3.5) ‒12.3 (43.0) NS
 IDL-apoB 4.0 (1.9) 2.6 (1.1) ‒29.9 (22.2) <0.0001
 LDL-apoB 71.2 (20.6) 30.4 (9.2) ‒56.3 (10.2) <0.0001
 VLDL-C 12.7 (7.3) 9.1 (4.9) ‒17.4 (48.7) 0.1
 IDL-C 5.6 (2.6) 3.0 (1.1) ‒41.1 (27.8) <0.0001
 LDL-C 89.3 (18.3) 39.8 (11.9) ‒55.1 (10.7) <0.0001
 VLDL-TG 55.0 (33.9) 48.6 (33.8) ‒4.1 (52.0) NS
 IDL-TG 6.9 (3.1) 5.1 (1.6) ‒20.9 (20.8) 0.0005
 LDL-TG 13.5 (3.9) 8.6 (2.2) ‒35.5 (10.4) <0.0001
All data are presented as absolute means, % change, and standard 
deviations (SD). apoB indicates apolipoprotein B; apoCIII, apolipoprotein 
CIII; apoE, apolipoprotein E; HDL-C, high-density lipoprotein-cholesterol; 
IDL, intermediate density lipoprotein; LDL, low density lipoprotein; LDL-C, 
low-density lipoprotein cholesterol; NS, not significant TG, triglycderides; 
and VLDL, very low density lipoprotein.
*Alirocumab administered every 2 weeks.
†Calculated using the Friedewald equation.
‡apoCIII, apoE, and sterol measurements were only measured in N=14 
participants who consented to future research use of their samples.
¶Lipoproteins isolated by ultracentrifugation.10
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alirocumab, including decreased secretion of VLDL (the 
major precursor of LDL), increased removal of VLDL or 
its remnants without conversion to IDL and then LDL, 
or, more likely, increased removal of IDL, a lipoprotein 
close to LDL in size and composition, without conversion 
to LDL. Importantly, statins, which increase the number 
of LDLRs by inhibiting hydroxymethylglutaryl-CoA reduc-
tase, the rate-limiting enzyme of cholesterol synthesis, 
have been demonstrated to have multiple effects on the 
metabolism of VLDL, IDL, and LDL.23,24 Thus, it seemed 
possible that, depending on the background lipid me-
tabolism present in any individual, one or more of the 
Figure 1. Effects of alirocumab on VLDL-, IDL-, and LDL–apoB fractional clearance rates (A) and production 
rates (B). 
FCRs of VLDL, IDL, and LDL-apoB (mean±SE) were determined by stable isotopic enrichment of apoB in each lipoproteins. PRs 
(mean±SE) were calculated using the FCRs and plasma pool size of apoB in each lipoprotein. Alirocumab treatment significantly 
increased the FCRs of IDL and LDL apoB and reduced the PR of LDL apoB compared with placebo. No significant effects of 
alirocumab on VLDL apoB metabolism were found. apoB indicates apolipoprotein B; FCR, fractional clearance rate; IDL, interme-
diate-density lipoprotein; LDL, low-density lipoprotein; ns, not significant; PR, production rate; SE, standard error; and VLDL, very 
low-density lipoprotein.
Figure 2. Effect of alirocumab on VLDL-TG fractional clearance rates (A) and production rates (B). 
FCR of VLDL-TG (mean±SE) was determined by stable isotopic enrichment of glycerol in each sample of isolated VLDL over 48 
hours. VLDL-TG PR (mean±SE) was calculated using the FCR and the plasma pool size of TG in VLDL. Alirocumab treatment did 
not affect either the FCR or the PR of VLDL-TG compared with placebo. FCR indicates fractional clearance rate; PR, production 
rate; TG, triglycerides; and VLDL, very low-density lipoprotein.








January 24, 2017 Circulation. 2017;135:352–362. DOI: 10.1161/CIRCULATIONAHA.116.025253358
scenarios described previously might be important in the 
lowering of LDL-C by inhibition of PCSK9.
In this study of healthy volunteers, it is clear that the 
major effect of alirocumab was to enhance the efficiency 
of LDL particle clearance from the circulation; the FCR for 
LDL-apoB increased by 80.4%. Because only 1 apoB per 
LDL particle exists, this increase in the FCR translates to 
nearly twice as many LDL particles cleared per day dur-
ing alirocumab treatment compared with placebo. Be-
cause LDLRs account for at least 80% of the clearance 
of LDL particles from the circulation, the near doubling 
of the FCR for LDL-apoB almost certainly resulted from 
a similar increase in available LDLRs on the surface of 
the liver.25 We also demonstrated a significant increase 
in the FCR of IDL-apoB, compatible with the known abil-
ity of LDLRs to bind and internalize a range of apoB-
lipoproteins. This increase in IDL-FCR was accompanied 
by greater direct removal of IDL-apoB, which resulted in 
a reduced LDL-apoB PR. Thus, two related mechanisms 
for the marked reductions in LDL-C and LDL-apoB lev-
els occurred during alirocumab therapy. An additional 
or alternative explanation for the increase in LDL-apoB 
FCR after alirocumab treatment could have been that 
changes in the physical-chemical characteristics of LDL 
particles would increase their affinity for the LDLR. For 
example, alirocumab might directly increase LDL par-
ticle size, and larger LDL particles have a greater affin-
ity for the LDLR.26 However, our finding that alirocumab 
treatment resulted in a shift in the distribution of LDL 
toward smaller particles is compatible with greater re-
moval of larger LDL particles by increased numbers of 
LDLR rather than a primary treatment-mediated shift in 
LDL toward larger particles.
In contrast to the findings for IDL and LDL, we saw no 
significant effect of alirocumab on VLDL-apoB and VLDL-
TG metabolism. Because VLDL-apoB or its remnants 
can interact with the LDLR, resulting in direct removal 
of VLDL particles from the circulation without conversion 
to LDL,6,8,27 the possibility existed that PCSK9 inhibition 
would be associated with an increased flux of VLDL par-
ticles through that pathway. The probability that VLDL will 
be converted to IDL and LDL by lipolysis rather than be-
ing internalized by LDLRs depends on the quantity of TG 
in each VLDL particle, with TG-rich VLDL particles more 
likely to be removed directly from plasma compared with 
smaller, TG-poor VLDL particles.28 We studied healthy in-
dividuals with normal plasma TG levels, and, therefore, 
lipolytic conversion to IDL and LDL was probably rapid, 
reducing the possibility of an interaction between VLDL 
and LDLRs in the hepatic bed. Lipolysis, which would be 
the dominant determinant of the fate of relatively TG-poor 
VLDL particles entering the circulation in our healthy vol-
Figure 3. Correlation between baseline serum-free PCSK9 levels and changes in (A) LDL-C and (B) LDL-apoB 
levels. 
Baseline levels of serum-free PCSK9 were examined for correlation with alirocumab-induced changes in LDL-C and LDL-apoB in 
all 18 subjects. Changes in both LDL-C and LDL-apoB were related to PCSK9 levels at baseline. apoB indicates apolipoprotein B; 
LDL, low-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; and PCSK9, proprotein convertase subtilisin/kexin type 9.
Table 3. Effects of Alirocumab on Lp(a) Plasma 
Levels and the Kinetics of apo(a)




























Lp(a) levels are expressed as medians with interquartile ranges for the 
percent changes (N=18). 
apo(a) indicates apolipoprotein(a); FCR, fractional clearance rate; Lp(a), 
lipoprotein(a); and PR, production rate.
*Lp(a) kinetics studies were performed on only 17 subjects because 
1 subject had levels of Lp(a) too low for liquid chromatography/mass 
spectrometry determination of enrichment.
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unteers, was not affected by alirocumab, as indicated 
by unchanged postheparin lipolytic activities and apoCIII 
levels. The decrease in apoE levels was most likely the 
result of increased fractional removal of apoE-containing 
IDL and LDL particles from the blood. However, lower 
apoE levels could have contributed to the lack of an in-
crease in direct removal of VLDL despite increased LDLR 
availability.
In addition to the potential for increased removal of 
VLDL by hepatic LDLRs, the effects of PCSK9 on the se-
cretion of apoB-lipoproteins have also been demonstrat-
ed. Overexpression of PCSK9 in either the liver or the 
intestine increases secretion of apoB-lipoproteins,29,30 
whereas knockdown of PCSK9 has the opposite ef-
fect.30,31 Additionally, individuals with gain-of-function 
mutations in PCSK9 were found to have increased se-
cretion of VLDL-, IDL-, and LDL-apoB.32 Our finding that 
alirocumab did not affect either VLDL PR or PP lipemia 
is, therefore, in contrast to these reports, but it is pos-
sible that these differences also reflect the absence of 
underlying abnormalities in either lipolysis- or receptor-
mediated removal of apoB48 particles in the individuals 
we studied. Alternatively, pharmacological interference 
with the action of circulating PCSK9 does not affect in-
tracellular actions of PCSK9 on VLDL or chylomicron 
secretion. Finally, studies with alirocumab and other 
monoclonal antibodies directed against PCSK9 in popu-
lations with elevated fasting TG levels may produce dif-
ferent results.
A theoretical concern related to the alirocumab-medi-
ated increase in LDL clearance from the circulation is an 
increase in the flux of LDL-C into the liver, with the po-
tential for steatosis or cholesterol gallstone formation. 
However, after an initial increase in hepatic uptake of 
IDL and LDL particles immediately after the first dose 
of alirocumab, a stable increase in the FCR of a smaller 
circulating pool of LDL particles will result in little or no 
change in the absolute rate of cholesterol uptake by the 
liver in a new steady state. The absence of significant 
changes in lathosterol, a measure of cholesterol syn-
thesis, or either sitosterol or campesterol, markers of 
cholesterol absorption, indicate hepatic cholesterol ho-
meostasis was maintained during chronic alirocumab 
therapy.33,34
The metabolism of Lp(a) remains poorly defined 50 
years after its discovery.35,36 Although plasma levels ap-
pear to be closely related to PR,36,37 understanding of the 
pathways involved in the clearance of Lp(a) remains mod-
est at best. Indeed, some studies indicate that neither the 
LDLR nor apoB plays a role in the removal of Lp(a) from 
the circulation,38,39 whereas others support a central role 
for the LDLR in the uptake of Lp(a) by hepatocytes.40 Ad-
ditional uncertainty arises from the observations that al-
though Lp(a) levels are increased in individuals with famil-
ial hypercholesterolemia,41 a disorder with reduced levels 
of LDLR, statins, which increase the FCR of LDL-apoB by 
25% to 40%, do not lower Lp(a) levels.11 It must be noted, 
however, that statins raise both the number of LDLR and 
Figure 4. Postprandial levels of 
TG (A) and ApoB48 (B) after a 
high-fat meal.  
(Left) Mean concentrations over time. 
(Right) Incremental area-under-the-
curve (IAUC). Ten participants had 
blood samples just before and at 1, 
2, 3, 5, and 8 hours after consuming 
a high-fat liquid meal providing 1237 
Kcal per 2 m2 body surface area from 
75% fat, 10% protein, and 15% car-
bohydrate The data are presented as 
individual timepoints (mean±SE) and 
area under the curve above baseline 
(IAUC) (mean±SE) of plasma TG and 
apoB48 concentrations. Alirocumab 
had no effects on postprandial levels 
of TG and apoB48 compared with 
placebo. apoB indicates apolipopro-
tein B; and TG, triglycerides. 
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plasma concentrations of PCSK9, with the latter effect 
negating, at least partially, the increase in LDLR.42 Treat-
ment of homozygous familial hypercholesterolemia pa-
tients with evolocumab was associated with reductions in 
Lp(a) levels, suggesting non-LDLR clearance of Lp(a), but 
only 1 of the 49 subjects reported was homozygous for 
a null mutation in the LDLR.43
Our results for Lp(a), which are suggestive and not 
conclusive, certainly do not rule out other complemen-
tary or alternative pathways for Lp(a) removal from the 
circulation. We also acknowledge studies of the simul-
taneous kinetics of both apo(a) and apoB demonstrat-
ing different FCRs for apo(a) and apoB, suggesting that 
they are not always linked on a single Lp(a) particle.44,45 
However, in a third study, it appeared that the 2 proteins 
were linked throughout their time in the circulation.46 Al-
though further work is required to fully define the stabil-
ity of the association between apo(a) and apoB in Lp(a), 
this potential complexity would not impact our findings 
because the FCR of apo(a) was determined in a similar 
fashion in our study and the others. Indeed, the FCRs of 
apo(a) in all 3 of those published reports were similar to 
those we determined in the present investigation. Finally, 
a study in which FCRs of apo(a) were determined by the 
rate of rise of plasma levels after physical removal of 
Lp(a) by apheresis reported rates nearly identical to the 
FCRs we found at baseline.47
In conclusion, inhibition of PCSK9 activity with ali-
rocumab treatment of healthy, normolipidemic volun-
teers reduced LDL-C and LDL-apoB concentrations by 
55% and 56%, respectively, in association with a nearly 
doubling of the efficiency with which LDL particles were 
removed from the circulation. A significant fall in LDL-
apoB PR caused by increased direct removal of IDL 
particles from the circulation was also found. Both of 
these findings are consistent with increased availability 
of LDLR on the surface of the liver, the main organ for 
LDL clearance. Lp(a) concentrations were reduced sig-
nificantly, with a strong trend toward an increased FCR, 
suggestive of a role for the LDLR in the clearance of 
Lp(a). Alirocumab did not have an effect on Lp(a) PR.
Of note, the potent effect of inhibition of PCSK9 ac-
tivity on the FCR of LDL-apoB observed in this study in-
dicates that individuals without dyslipidemia continually 
lose ≥50% of LDLRs to lysosomal degradation because 
of the actions of PCSK9. The number of LDLRs on cell 
surfaces is exquisitely regulated at the transcriptional lev-
el by effects of the concentration of hepatic-free choles-
terol on the sterol response element binding protein-2,48 
raising the interesting question as to why we evolved with 
PCSK9 as a parallel regulator of LDL uptake.
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Figure 5. Role of PCSK9 in LDL metabolism and im-
pact of PCSK9 monoclonal antibody.  
(A) (1) LDLR binds to LDL particle at the liver cell surface. 
PCSK9 can also bind to the LDLR. (2) The LDL particle‒LDLR 
complexes with or without PCSK9 bound are internalized in 
the liver cell by endocytosis. (3) LDLR not bound to PCSK9 
release the LDL particle, which goes to a lysosome for 
digestion, whereas the LDLR is recycled to the cell surface. 
(4) LDLR bound to PCSK9 is digested in the lysosome along 
with the LDL particle. (B) (1) PCSK9 mAb binds PCSK9 in the 
circulation, preventing it from binding the LDLR. (2) The LDL 
particle‒LDLR complexes are internalized in the liver cell. (3) 
In the absence of PCSK9 binding, increased LDLR receptor 
recycling and more LDLR on the liver cell surface to bind 
result. (4) Circulating LDL particle levels are reduced. LDL in-
dicates  low-density lipoprotein; LDLR, low-density lipoprotein 
receptor; mAb, monoclonal antibody; and PCSK9, proprotein 
convertase subtilisin/kexin type 9.
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SUPPLEMENTAL MATERIAL  
Study Safety:  
The safety of alirocumab and its effects on blood lipids have been previously reported 
for men and women receiving repeated subcutaneous doses as high as 150 mg every 2 
weeks (q2w) and 300 mg every four weeks.1, 2 Each subject received a physical 
examination, ECG, and collection of blood and urine for laboratory safety assessments 
during the study in-patient visits.  The subjects returned about 10 weeks after the last 
study dose, when systemic exposure to alirocumab was negligible, for final safety 
assessments.  
There were no deaths and no serious adverse events in the study. There were no 
treatment discontinuations due to an adverse event in the study. In the safety population 
(N=20) there were 15 subjects with any treatment-emergent adverse event (TEAE), and 
1 subject with a severe TEAE. The most frequent TEAEs by Primary System Organ 
Class and Preferred Term were Infections and infestations with 7 subjects 
(Nasopharyngitis [6] , Gingivitis [1]), General disorders and administration site 
conditions with 4 (Injection site reaction [3], Infusion site bruising [1], Vessel puncture 
site bruise [1]), and Nervous system disorders with 3 (Headache [3], Dizziness [1]). For 
vital signs, electrocardiograms, and laboratory parameters, there were no potentially 
clinically significant abnormalities that were associated with an adverse event.  
Anti-drug antibody (ADA) samples from a total of 18 subjects who were dosed with 150 
mg alirocumab q2w were analyzed in this study. Three samples from 3 subjects had a 
2 
 
positive response in the ADA assay. Two subjects had a treatment emergent ADA 
response. One subject was positive at Day 1 with a titer of 30, but had no positive ADA 
response in the post-dose samples.  
Methods:  
Hepatic Lipase (HL) and Lipoprotein Lipase (LpL) Activity Measurements: Fasting 
plasma was collected 15 minutes following an intravenous heparin injection (60 U/kg 
body weight) at the end of each treatment period for measurement of LpL and HL 
concentration and activity.  Post heparin plasma (PHP) total lipase activities were 
assayed in triplicate using radiolabeled TG emulsion as a substrate.3, 4  Results were 
expressed as µmol of FA released per ml per hr.  The contribution of HL was determined 
by including 1 M NaCl in the assay; the activity of HL was subtracted from the total 
lipase activity to estimate LpL.  
Post Prandial Lipemia:  Participants were admitted to the Irving Institute for Clinical 
and Translational Research Inpatient Unit after a 12 hour overnight fast, and blood was 
obtained. Immediately after, a high fat liquid meal providing 1237 Kcal per 2m2 body 
surface area from 75% fat (40% saturated, 20% mono-unsaturated, 15% poly-
unsaturated), 10% protein, and 15% carbohydrate, was administered within 10 minutes.  
Blood samples were obtained at 1, 2, 3, and 5 and 8 hours after the formula was 
consumed. The data are presented as area under the curve above baseline (IAUC) of 












Table S1: Effect of Alirocumab on VLDL-, IDL-, and LDL-apoB particle number by 
ion mobility analysis.   
 
Total Lipoprotein Particle Number (nmol/l) 
  Placebo Alirocumab % change 
(±SD) 
p-value 
LDL 180-233.3 1250.2 889.8 -28.4±16.4 <.0001 
IDL 233.3-296.0 392.3 269.2 -31.6±18.2 <.0001 




Table S2: LDL particle number distribution   
 
Lipoprotein particle number distribution    








Very small (180-205) 
33.6±6.7% 27.3±5.4% <.0001 
33.9±4.0% 30.5±2.2% <.003 
15.2±4.2% 18.2±3.4% <.0001 
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